The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. TransCode Therapeutics Inc’s current trading price is -97.96% away from its 52-week high, while its distance from the 52-week low is 75.93%. The stock’s price range for this period has been between $0.22 and $18.66 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 0.52 million for the day, a number notably lower than the average daily volume of 1.66 million over the last three months.
TransCode Therapeutics Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $18.66 on 11/30/23, while the lowest value for the same period was recorded at $0.22 on 08/14/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
TransCode Therapeutics Inc (RNAZ) has experienced a quarterly rise of 39.65% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 6.56M and boasts a workforce of 10 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.4601, with a change in price of -0.5600. Similarly, TransCode Therapeutics Inc recorded 1,570,254 in trading volume during the last 100 days, posting a change of -59.57%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for RNAZ stands at 0.09. Similarly, the long-term debt-to-equity ratio is also 0.00.
RNAZ Stock Stochastic Average
As of today, TransCode Therapeutics Inc’s raw stochastic average for the last 50 days stands at 23.64%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 19.03%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 9.45% and 6.03%, respectively.
RNAZ Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. The metric has seen a significant loss of -94.24% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -72.66%. Over the past 30 days, the price of RNAZ has leaped by -43.54%. And in the last five days, it has surged by 8.60%.
